New Indication: Perioperative Nivolumab and Chemotherapy for Stage III NSCLC

A Phase II , Randomized, Open-label , multicenter trial

Resectable, stage IIIA or IIIB NSCLC

Arm A: Nivolumab + Carboplatin + PaclitaxelS->Nivolumab (n=57)

Arm B: Carboplatin + Paclitaxel S->PBO (n=29)

24 mos PFS: 67.2% vs 40.9%

24 mos OS: 85.0% vs. 63.6%

mPR: 53.0% vs 14.0%

PcR: 37.0% vs. 7.0%

Grade3: febrile neutropenia (7% vs.0%), fatigue (4% vs.3%), diarrhea (4% vs.0)

Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023

nivolumab